Rising Alzheimer’s rates prompt federal aid and new scientific findings on disease prevention and detection

According to the National Institute on Aging, 6.9 million Americans are living with Alzheimer’s disease today. As the ...
Pharmabiz

Health ministry to amend Drugs Rules to allow UP based CCSNIAH to test more veterinary vaccines

Gireesh Babu, New Delhi Wednesday, February 4, 2026, 08:00 Hrs [IST] ...
EurekAlert!

Dr. Àlex Bayés Puig advances SYNGAP1 research with new SynGAP biomarker study funded by CURE SYNGAP1

CURE SYNGAP1, a 501(c)(3) organization, is proud to announce the award of a $25,000 grant to Dr. Àlex Bayés Puig, Group ...

Axon Neuroscience’s Immunotherapy Selected for a Landmark Combination-Therapy Alzheimer’s Clinical Trial in US, Supported by a USD 151 Million Grant

Axon Neuroscience's active tau immunotherapy AADvac1 has been selected as the first tau-targeted therapy to enter a ...

Axon Neuroscience's Immunotherapy Selected for Landmark Combination-Therapy Alzheimer’s Clinical Trial in U.S., Supported by $151 Million Grant

Axon Neuroscience’s active tau immunotherapy, AADvac1, has been selected as the first tau-targeted therapy to enter a ...
Le Lézard

Oncolytic Virus Clinical Trial Landscape Gains Momentum: 100+ Companies Lead the Charge in Pioneering New Treatments | DelveInsight

DelveInsight's Oncolytic Virus Competitive Landscape 2026 report provides comprehensive global coverage of pipeline oncolytic virus therapies across various stages of clinical development. The report ...

Axon Neuroscience, a.s.: Axon Neuroscience's Immunotherapy Selected for a Landmark Combination-Therapy Alzheimer's Clinical Trial in US, Supported by a USD 151 Million Grant

Axon Neuroscience's active tau immunotherapy AADvac1 has been selected as the first tau-targeted therapy to enter a groundbreaking U.S. Alzheimer's disease phase 2 clinical trial (supported by a USD 1 ...